Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.
Schneider-Helmert. D D; Gnirss. F F; Monnier. M M; Schenker. J J; Schoenenberger. G A GA
Key Findings
- A single IV dose of 25 nmol/kg DSIP caused an immediate feeling of sleep pressure.
- Total sleep time increased by roughly 59% in the 130‑minute window after dosing compared with placebo.
- During the following night, participants fell asleep faster, had less stage‑1 sleep, and showed improved sleep efficiency, without any reported adverse effects.
Practical Outcomes
- DSIP appears to boost natural sleep processes without typical drug sedation, suggesting it could be explored as a sleep‑enhancing tool. However, the study used IV infusion and involved only six subjects, so the protocol isn’t ready for at‑home use. Enthusiasts might consider the dosage (25 nmol/kg) and timing (morning) as a starting point for further self‑experimentation, but should proceed cautiously and monitor sleep metrics closely.
Summary
A tiny study gave six healthy people a short IV dose of synthetic DSIP and found they felt sleepy right away and slept about 60% longer in the next two hours. That night they fell asleep faster, spent less time in light sleep, and had better overall sleep quality. No side effects or classic drug‑like sedation were seen.
Abstract
A first study of DSIP (= synthetic delta sleep-inducing peptide) application to humans was carried out in six normal volunteers (four males and two females) under extensive psychophysiologic observations and measurements in a double-blind cross-over design. DSIP was applied as slow intravenous infusions at a dosage of 25 nmol/kg in the morning. The subjects immediately reported a feeling of sleep pressure, and sleep increased by 59% (median of total sleep time) within a 130-min interval after the treatment as compared with placebo. Delayed effects on subsequent night sleep were shorter sleep onset, reduced percentage of stage 1, and better sleep efficiency. Nevertheless, sophisticated behavioral and EEG analyses revealed no sedation in the classic pharmacologic way. The results suggest that DSIP in humans is also efficacious by sustaining natural sleep functions. The compound was well-tolerated and no psychologic, physiologic, or biochemical side effects were observed.
Study Information
pubmed
1981